Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies
Nele Boeckx(University of Antwerp), Marc Peeters(Ghent University Hospital), Salvatore Siena(University of Milan), Reija Koukakis(Amgen (United Kingdom)), Ken Op de Beeck(Antwerp University Hospital), Christian Rolfo(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Thierry André(Sorbonne Université), Guy Van Camp(University of Antwerp), Jean‐Yves Douillard(European Society for Medical Oncology), Josep Tabernero(Universitat de Vic - Universitat Central de Catalunya)
Cited by 219
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k